Format

Send to

Choose Destination
Value Health Reg Issues. 2016 Dec;11:9-16. doi: 10.1016/j.vhri.2015.11.002. Epub 2016 Feb 10.

Costo- Efectividad Del Uso Profiláctico Del Factor Estimulante De Colonias De Granulocitos En Adultos Con Leucemia Linfoblástica Aguda en Colombia.

Author information

1
Centro Dermatológico Federico Lleras Acosta E.S.E., Bogotá D. C., Colombia. Electronic address: casavieja2032@gmail.com.
2
Universidad Nacional de Colombia, Bogotá D. C., Colombia.
3
Instituto Nacional de Cancerología, Bogotá D, C., Colombia.

Abstract

OBJECTIVE:

To assess the cost-effectiveness of prophylactic administration of Granulocyte Colony-Stimulating Factor (G-CSF) compared with no use of it, during the induction phase of chemotherapy in Adults with Acute Lymphoblastic Leukemia (ALL) in Colombia.

METHODS:

A decision tree with a time horizon of 30 days was built under colombian health system perspective including only direct costs. The costs of procedures and medications were taken from official sources and an institution of national reference of oncology services. The safety and effectiveness data were taken from the literature and two Colombian cohorts with patients older than 15 years. The unit of outcome was the proportion of deaths avoided.

RESULTS:

Base-case results on a clinical trial indicate that using factor is a dominant strategy. The variable that most impacted the outcome was the incidence of febrile neutropenia. Considering a threshold of $22.228 USD in 80% of cases using factor was cost effective. However, the use of factor is not cost-effective for the country for incidences of febrile neutropenia > 48%. It was not possible to establish cost-effectiveness of pegfilgrastim because no information was found.

CONCLUSION:

As per Colombian data, the use of prophylactic factor under chemotherapeutic induction in adults with ALL, turns out to be not cost effective. The difference in the results suggests the need of a careful extrapolation of information from clinical trials (ideal world) for developing economic evaluations in Colombia.

KEYWORDS:

Colombia; Cost- Effectiveness Analysis; Febrile Neutropenia; Filgrastim; Granulocyte Colony-Stimulating Factor; Leukemia; Pegfilgrastim

PMID:
27986205
DOI:
10.1016/j.vhri.2015.11.002
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center